ProShares UltraPro Short NASDAQ Biotechnology
ZBIO
ZBIO was delisted on the 27th of March, 2020.
7 hedge funds and large institutions have $995K invested in ProShares UltraPro Short NASDAQ Biotechnology in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
47% more capital invested
Capital invested by funds: $677K → $995K (+$318K)
40% more funds holding
Funds holding: 5 → 7 (+2)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$385K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$30.1K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$22.9K |
| 4 |
Morgan Stanley
New York
|
+$12.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$93.6K |
| 2 |
VF
Virtu Financial
New York
|
-$11K |
| 3 |
CG
Cutler Group
San Francisco,
California
|
-$7.84K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $411K | +$385K | +19,668 | New |
|
|
VF
2
Virtu Financial
New York
| $269K | -$11K | -561 | -4% |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $208K | -$93.6K | -4,779 | -32% |
|
|
4
UBS Group
Zurich,
Switzerland
| $35K | +$9.66K | +493 | +42% |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $32K | +$30.1K | +1,535 | New |
|
|
6
Simplex Trading
Chicago,
Illinois
| $24K | +$22.9K | +1,169 | New |
|
|
7
Morgan Stanley
New York
| $16K | +$12.2K | +621 | +370% |
|
|
CG
8
Cutler Group
San Francisco,
California
| – | -$7.84K | -400 | Closed |
|
ZBIO Hedge Fund Activity: Q1 2018 in Review
7 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) for Q1 2018, worth a combined $995K — up 47% from $677K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ZBIO positions and 1 closed out — a net gain of 2 holders — while 2 added to existing stakes and 2 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $385K. The largest seller was Susquehanna International Group, cutting an estimated $93.6K.
- 7 institutional investors held ProShares UltraPro Short NASDAQ Biotechnology (ZBIO) as of Q1 2018, up from 5 in Q4 2017.
- Funds reported $995K of ProShares UltraPro Short NASDAQ Biotechnology stock for Q1 2018, up 47% quarter-over-quarter.
- 3 funds opened new ProShares UltraPro Short NASDAQ Biotechnology positions in Q1 2018 and 1 closed out, a net change of +2 holders.
- The largest ProShares UltraPro Short NASDAQ Biotechnology buyer in Q1 2018 was Jane Street, an estimated $385K added.
- The largest ProShares UltraPro Short NASDAQ Biotechnology seller in Q1 2018 was Susquehanna International Group, an estimated $93.6K sold.
Based on aggregated 13F filings for Q1 2018.